# Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

> **NCT07728721** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 175 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** HSK50042 dose 1
- **DRUG:** HSK50042 dose 2
- **DRUG:** HSK50042 dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07728721
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2028-04-10
- **Final completion:** 2028-07-25
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728721, "Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07728721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*